European regulators have ordered a recall of all batches of Amgen’s Tavneos (avacopan) after the European Commission canceled the drug’s marketing authorization for the vasculitis treatment earlier this month. The recall affects patient access and raises immediate compliance questions for distributors and prescribing physicians across EU markets. The action underscores how quickly established products can lose market authorization when the underlying EU review outcome turns against continued commercialization. For biotech and pharma teams, it also highlights the importance of monitoring not just national decisions but EU-level determinations tied to authorization status.